• Written informed concent
• Age at least 18 years
• WHO Performance status 0-3
• Histologically verified B-cell lymphoma
• Diffuse large B-cell lymphoma and follicular grade III, failing an anthracycline containing regimen and patients not found suitable for a second line chemotherapy consolidated by HDCT with stem cell support or radiotherapy
• Transformed B-cell lymphoma, failing first line therapy and not suitable for HDCT or with a history of HDCT with stem cell support
• Follicular lymphoma grade II and I, and other indolent lymphomas must have failed second line treatment
• One of these treatments must have contained chemotherapy and rituximab, the latter either together with chemotherapy or as maintenance
• The lymphoma must require treatment, Mantle cell lymphoma, failing first line treatment,treatment required
• Measurable disease and the tumor burden must be acceptable according to the investigator
• Radiological studies must be performed and a unilateral bone marrow biopsy within 4 weeks before start of treatment
• Bone marrow reserve likely to give a harvest of at least 2x10 6 peripheral CD34+ stemcells or the existence of such a harvest or a corresponding central harvest
• Total bilirubin should not exceed 40 micromole/L
• A GFR as measured by Cystatin C of
  50 ml/min
• HIV, Hepatitis B and C status known
• Life expectancy of at least 3 months.

Zevalin + autologt stamcellsstöd